{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T13:14:14Z","timestamp":1788354854905,"version":"build-2803163510"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004775","name":"Natural Science Foundation of Gansu Province","doi-asserted-by":"crossref","award":["23JRRA1288"],"award-info":[{"award-number":["23JRRA1288"]}],"id":[{"id":"10.13039\/501100004775","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Gansu Provincial Drug Research Project","award":["2025GSMPA063"],"award-info":[{"award-number":["2025GSMPA063"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01584-x","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:16:25Z","timestamp":1788351385000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Research Progress and Optimization Strategies of Bispecific Antibody Therapies for CLDN18.2-Positive Gastric Cancer"],"prefix":"10.1007","volume":"57","author":[{"given":"Panpan","family":"Ji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanhong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"issue":"9","key":"1584_CR1","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1038\/s41591-025-03793-6","volume":"31","author":"JY Park","year":"2025","unstructured":"Park JY, Georges D, Alberts CJ, Bray F, Clifford G, Baussano I. Global lifetime estimates of expected and preventable gastric cancers across 185 countries. Nat Med. 2025;31(9):3020\u201327. https:\/\/doi.org\/10.1038\/s41591-025-03793-6.","journal-title":"Nat Med"},{"issue":"10","key":"1584_CR2","doi-asserted-by":"publisher","first-page":"113491","DOI":"10.1016\/j.isci.2025.113491","volume":"28","author":"Y Liu","year":"2025","unstructured":"Liu Y, Huang W, Hsu JC, Sun Z, Cai W, Kang L. Targeting Claudin18.2 for cancer theranostics: From molecular imaging to precision therapy. iScience. 2025;28(10):113491. https:\/\/doi.org\/10.1016\/j.isci.2025.113491.","journal-title":"iScience"},{"key":"1584_CR3","doi-asserted-by":"publisher","unstructured":"Egebjerg K, Lordick F, Liu LL, Dahlgaard NB, Mau-S\u00f8rensen M. Zolbetuximab as a gastric lineage-directed immunotherapy: mechanistic rationale and translational evidence in CLDN18.2-positive gastroesophageal adenocarcinoma. Expert Rev Anticancer Ther. 2026;1\u201311. https:\/\/doi.org\/10.1080\/14737140.2026.2615855.","DOI":"10.1080\/14737140.2026.2615855"},{"issue":"10389","key":"1584_CR4","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/s0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401(10389):1655\u201368. https:\/\/doi.org\/10.1016\/s0140-6736(23)00620-7.","journal-title":"Lancet"},{"key":"1584_CR5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-26-0708","author":"M Nikanjam","year":"2026","unstructured":"Nikanjam M, P\u00e9rez-Granado J, Gramling MW, Larvol B, Kurzrock R. Claudin 18.2 Targeting: A Pan-Cancer Perspective. Clin Cancer Res. 2026. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-26-0708.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1584_CR6","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12943-025-02390-y","volume":"24","author":"L Shui","year":"2025","unstructured":"Shui L, Wu D, Yang K, Sun C, Li Q, Yin R. Bispecific antibodies: unleashing a new era in oncology treatment. Mol Cancer. 2025;24(1):212. https:\/\/doi.org\/10.1186\/s12943-025-02390-y.","journal-title":"Mol Cancer"},{"issue":"5","key":"1584_CR7","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/s41571-024-00874-2","volume":"21","author":"I Nakayama","year":"2024","unstructured":"Nakayama I, Qi C, Chen Y, Nakamura Y, Shen L, Shitara K. Claudin 18.2 as a novel therapeutic target. Nat Rev Clin Oncol. 2024;21(5):354\u201369. https:\/\/doi.org\/10.1038\/s41571-024-00874-2.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"1584_CR8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/14712598.2026.2617271","volume":"26","author":"K Yamamoto","year":"2026","unstructured":"Yamamoto K, Nakayama I, Shitara K. Targeting claudin 18.2 in gastric cancer: a review of emerging biologic agents. Expert Opin Biol Ther. 2026;26(1):65\u201380. https:\/\/doi.org\/10.1080\/14712598.2026.2617271.","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"1584_CR9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/PAI.0000000000001248","volume":"33","author":"JL Gros","year":"2025","unstructured":"Gros JL, D\u00edaz PS, Loring ML, Patriarca ME, Lloveras B, Iglesias M. Claudin 18.2 immunohistochemistry expression in gastric cancer: a systematic review. Appl Immunohistochem Mol Morphol. 2025;33(2):61\u20139.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"24","key":"1584_CR10","doi-asserted-by":"publisher","first-page":"e202500575","DOI":"10.1002\/cbic.202500575","volume":"26","author":"Z Yuan","year":"2025","unstructured":"Yuan Z, Yang X, Jin H, Cui S, Li JB. Strategies for the Generation of Bispecific Antibodies. ChemBioChem. 2025;26(24):e202500575. https:\/\/doi.org\/10.1002\/cbic.202500575.","journal-title":"ChemBioChem"},{"key":"1584_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/0003-9861(61)90296-x","author":"A Nisonoff","year":"1961","unstructured":"Nisonoff A, Rivers MM. Recombination of a mixture of univalent antibody fragments of different specificity. Arch Biochem Biophys. 1961. https:\/\/doi.org\/10.1016\/0003-9861(61)90296-x. 93460-2.","journal-title":"Arch Biochem Biophys"},{"key":"1584_CR12","doi-asserted-by":"publisher","unstructured":"Ma J, Mo Y, Tang M, Shen J, Qi Y, Zhao W, et al. Bispecific antibodies: from research to clinical application. Front Immunol. 2021;12626616. https:\/\/doi.org\/10.3389\/fimmu.2021.626616.","DOI":"10.3389\/fimmu.2021.626616"},{"issue":"12","key":"1584_CR13","doi-asserted-by":"publisher","first-page":"114203","DOI":"10.1016\/j.isci.2025.114203","volume":"28","author":"S Zhou","year":"2025","unstructured":"Zhou S, Li F, Niu M, Wu K, Li T, Yi M. Advances in the clinical application of bispecific antibodies in cancer therapy. iScience. 2025;28(12):114203. https:\/\/doi.org\/10.1016\/j.isci.2025.114203.","journal-title":"iScience"},{"key":"1584_CR14","doi-asserted-by":"publisher","unstructured":"Zarampouka K, Tsiantas C, Stavropoulou MA, Efthymiadis K, Theotokis P, Gargani S, et al. Correlation of CLDN18.2 and Tumor Microenvironment in Gastric Cancer: A Systematic Review. Cancers (Basel). 2025;17(13). https:\/\/doi.org\/10.3390\/cancers17132120.","DOI":"10.3390\/cancers17132120"},{"issue":"1","key":"1584_CR15","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12916-022-02421-1","volume":"20","author":"K Jia","year":"2022","unstructured":"Jia K, Chen Y, Sun Y, Hu Y, Jiao L, Ma J, et al. Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer. BMC Med. 2022;20(1):223. https:\/\/doi.org\/10.1186\/s12916-022-02421-1.","journal-title":"BMC Med"},{"key":"1584_CR16","doi-asserted-by":"publisher","unstructured":"Lim SH, Kuwata T, An M, Hong JY, Kim ST, Matsubara Y, et al. Dynamic modulation of claudin18.2 expression and remodeling of the tumor microenvironment in gastric cancer during chemo-immunotherapy. J Immunother Cancer. 2025;13(9). https:\/\/doi.org\/10.1136\/jitc-2025-012683.","DOI":"10.1136\/jitc-2025-012683"},{"issue":"1","key":"1584_CR17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12916-025-04597-8","volume":"24","author":"X Li","year":"2026","unstructured":"Li X, Dai R, Xu Q, Guo Z, Hu C, Sun Y, et al. Safety and preliminary efficacy results of IBI389, an anti-Claudin18.2\u00d7CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: a phase 1 dose escalation and expansion study. BMC Med. 2026;24(1):91. https:\/\/doi.org\/10.1186\/s12916-025-04597-8.","journal-title":"BMC Med"},{"issue":"16","key":"1584_CR18","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1200\/JCO.2025.43.16_suppl.2527","volume":"43","author":"Y Wang","year":"2025","unstructured":"Wang Y, Gong J, Zhang M, Sun Y, Yang S, Lv J, et al. Safety and efficacy of QLS31905 in patients with advanced solid tumors: Updated data from phase 1 study. J Clin Oncol. 2025;43(16):2527. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.2527.","journal-title":"J Clin Oncol"},{"key":"1584_CR19","doi-asserted-by":"crossref","unstructured":"Zhang X, Zhang Z, Yang S, Zhang Y, Wang F, Yang W, et al. First-line treatment of QLS31905 plus chemotherapy in patients with pancreatic cancer and gastric cancer: Data from a phase 1b\/2 study [Z]. American Society of Clinical Oncology; 2026.","DOI":"10.1200\/JCO.2026.44.16_suppl.4003"},{"issue":"2","key":"1584_CR20","doi-asserted-by":"publisher","first-page":"S1202","DOI":"10.1016\/j.annonc.2025.08.275","volume":"36","author":"F Dayyani","year":"2025","unstructured":"Dayyani F, Strickler J, Hara K, Kasi A, Kitano S, Mahalingam D, et al. 2136P ASP2138 monotherapy or in combination with pembrolizumab and mFOLFOX6 or with ramucirumab and paclitaxel in claudin 18 isoform 2 (CLDN18. 2)+ locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG\/GEJ) adenocarcinoma: Phase I\/Ib trial. Ann Oncol. 2025;36(2):S1202. https:\/\/doi.org\/10.1016\/j.annonc.2025.08.275.","journal-title":"Ann Oncol"},{"issue":"23","key":"1584_CR21","doi-asserted-by":"publisher","first-page":"4944","DOI":"10.1158\/1078-0432.Ccr-24-4280","volume":"31","author":"G Ku","year":"2025","unstructured":"Ku G, Shen L, Dayyani F, Kratz J, Liang X, Liu F, et al. A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors. Clin Cancer Res. 2025;31(23):4944\u201352. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-24-4280.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1584_CR22","doi-asserted-by":"publisher","first-page":"S151","DOI":"10.1016\/j.annonc.2025.05.404","volume":"36","author":"S Klempner","year":"2025","unstructured":"Klempner S, Dayyani F, Kratz J, Kim S, Xu C, Ahlers C, et al. 388MO Preliminary safety and efficacy of givastomig, a novel claudin 18.2\/4-1BB bispecific antibody, in combination with nivolumab and mFOLFOX in metastatic gastroesophageal carcinoma (mGEC). Ann Oncol. 2025;36(1):S151\u201352. https:\/\/doi.org\/10.1016\/j.annonc.2025.05.404.","journal-title":"Ann Oncol"},{"issue":"16","key":"1584_CR23","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1200\/JCO.2024.42.16_suppl.2662","volume":"42","author":"Y Guo","year":"2024","unstructured":"Guo Y, Wu L, Li Y, Wen J, Xue J, Wang Z, et al. First-in-human phase I\/II safety and preliminary efficacy of PM1032, a bispecific antibody targeting CLDN18. 2 and 4-1BB, in patients with advanced solid tumors. J Clin Oncol. 2024;42(16):2662. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.2662.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1584_CR24","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1200\/JCO.2023.41.4_suppl.382","volume":"41","author":"W Yk","year":"2023","unstructured":"Yk W, Gong J, Sun Y, Zhang J, Ni S, Hou J, et al. Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18. 2\/PD-L1 bsABs, in patients with relapsed or refractory solid tumors. J Clin Oncol. 2023;41(4):382. https:\/\/doi.org\/10.1200\/JCO.2023.41.4_suppl.382.","journal-title":"J Clin Oncol"},{"key":"1584_CR25","doi-asserted-by":"crossref","unstructured":"Gong J, Wang Y, Sun Y, Ni S, Yang J, Zhang Y, et al. Phase I\/II trial of anti-CLDN18. 2\/PD-L1 recombinant humanized bispecific antibody Q-1802 plus XELOX in treatment-naive CLDN18. 2-positive advanced GC\/GEJ [Z]. American Society of Clinical Oncology; 2026.","DOI":"10.1200\/JCO.2026.44.16_suppl.4036"},{"issue":"2","key":"1584_CR26","doi-asserted-by":"publisher","first-page":"S933","DOI":"10.1016\/j.annonc.2024.08.159","volume":"35","author":"M Overman","year":"2024","unstructured":"Overman M, Laeufle R, Singh H, Henry J, Spira A, Chisamore M, et al. 1531TiP TWINPEAK phase I\/II study, PT886 a bispecific antibody targeting claudin 18.2 and CD47 in combination with chemotherapy and\/or pembrolizumab in gastric\/GEJ-carcinomas or PDAC. Ann Oncol. 2024;35(2):S933\u201334. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.159.","journal-title":"Ann Oncol"},{"issue":"4","key":"1584_CR27","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.3390\/cancers15041189","volume":"15","author":"AP Menon","year":"2023","unstructured":"Menon AP, Moreno B, Meraviglia-Crivelli D, Nonatelli F, Villanueva H, Barainka M, et al. Modulating T cell responses by targeting CD3. Cancers (Basel). 2023;15(4):1189. https:\/\/doi.org\/10.3390\/cancers15041189.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1584_CR28","doi-asserted-by":"publisher","first-page":"ltae005","DOI":"10.1093\/immadv\/ltae005","volume":"5","author":"L Dewaele","year":"2025","unstructured":"Dewaele L, Fernandes RA. Bispecific T-cell engagers for the recruitment of T cells in solid tumors: a literature review. Immunother Adv. 2025;5(1):ltae005. https:\/\/doi.org\/10.1093\/immadv\/ltae005.","journal-title":"Immunother Adv"},{"issue":"5","key":"1584_CR29","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/cpt.651","volume":"101","author":"T Yuraszeck","year":"2017","unstructured":"Yuraszeck T, Kasichayanula S, Benjamin JE. Translation and Clinical Development of Bispecific T-cell Engaging Antibodies for Cancer Treatment. Clin Pharmacol Ther. 2017;101(5):634\u201345. https:\/\/doi.org\/10.1002\/cpt.651.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"1584_CR30","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1053\/j.gastro.2023.06.037","volume":"165","author":"Y Xu","year":"2023","unstructured":"Xu Y, Fu J, Henderson M, Lee F, Jurcak N, Henn A, et al. CLDN18.2 BiTE Engages Effector and Regulatory T Cells for Antitumor Immune Response in Preclinical Models of Pancreatic Cancer. Gastroenterology. 2023;165(5):1219\u201332. https:\/\/doi.org\/10.1053\/j.gastro.2023.06.037.","journal-title":"Gastroenterology"},{"issue":"3","key":"1584_CR31","doi-asserted-by":"publisher","first-page":"212","DOI":"10.21037\/tcr-2026-0474","volume":"15","author":"Y Zhu","year":"2026","unstructured":"Zhu Y, Liu X, Zhang C, Zhou S, Ye D, Tang Q, et al. The claudin-18.2-CD3 bispecific antibody IBI389 exerts an antitumor effect on malignant tumors with positive claudin-18.2 expression by promoting T-cell infiltration and remodeling the tumor immune microenvironment. Transl Cancer Res. 2026;15(3):212. https:\/\/doi.org\/10.21037\/tcr-2026-0474.","journal-title":"Transl Cancer Res"},{"issue":"12Supplement","key":"1584_CR32","doi-asserted-by":"publisher","first-page":"5551","DOI":"10.1158\/1538-7445.AM2022-5551","volume":"82","author":"J Jiang","year":"2022","unstructured":"Jiang J, Si M, Luo X, Wu Y, Li Y, Yan X. QLS31905, an anti-claudin 18.2\/CD3 bispecific antibody for claudin 18.2-positive gastric cancer. Cancer Res. 2022;82(12Supplement):5551\u201351. https:\/\/doi.org\/10.1158\/1538-7445.AM2022-5551.","journal-title":"Cancer Res"},{"issue":"7","key":"1584_CR33","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1158\/1538-7445.AM2023-2962","volume":"83","author":"T Nakazawa","year":"2023","unstructured":"Nakazawa T, Tanaka H, Kikuchi A, Rashid R, Avery KN, Qi J, et al. ASP2138, a novel 2\u2009+\u20091 format, claudin 18.2 x CD3 bispecific antibody, demonstrates selectivity and activity in preclinical cancer models. Cancer Res. 2023;83(7):2962. https:\/\/doi.org\/10.1158\/1538-7445.AM2023-2962.","journal-title":"Cancer Res"},{"issue":"1","key":"1584_CR34","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s12276-023-01136-4","volume":"56","author":"R Singh","year":"2024","unstructured":"Singh R, Kim YH, Lee SJ, Eom HS, Choi BK. 4-1BB immunotherapy: advances and hurdles. Exp Mol Med. 2024;56(1):32\u20139. https:\/\/doi.org\/10.1038\/s12276-023-01136-4.","journal-title":"Exp Mol Med"},{"issue":"3","key":"1584_CR35","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1177\/10915818231221282","volume":"43","author":"J Wang","year":"2024","unstructured":"Wang J, Dong T, Gong X, Li D, Sun J, Luo Y, et al. Safety and pharmacokinetic assessment of the FIC CLDN18. 2\/4-1BB bispecific antibody in rhesus monkeys. Int J Toxicol. 2024;43(3):291\u2013300. https:\/\/doi.org\/10.1177\/10915818231221282.","journal-title":"Int J Toxicol"},{"issue":"6","key":"1584_CR36","doi-asserted-by":"publisher","first-page":"e006704","DOI":"10.1136\/jitc-2023-006704","volume":"11","author":"J Gao","year":"2023","unstructured":"Gao J, Wang Z, Jiang W, Zhang Y, Meng Z, Niu Y, et al. CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation. J Immunother Cancer. 2023;11(6):e006704. https:\/\/doi.org\/10.1136\/jitc-2023-006704.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"1584_CR37","doi-asserted-by":"publisher","first-page":"112615","DOI":"10.1016\/j.isci.2025.112615","volume":"28","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Yin K, Ma R, Sun Y, Wang L, Yin D. Complex regulatory network of programmed death-ligand 1 in cancer: Cancer immunomodulation from molecular mechanisms to clinical applications. Iscience. 2025;28(6):112615. https:\/\/doi.org\/10.1016\/j.isci.2025.112615.","journal-title":"Iscience"},{"issue":"9","key":"1584_CR38","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1002\/cam4.478","volume":"4","author":"K Yoshida","year":"2015","unstructured":"Yoshida K, Tsujimoto H, Matsumura K, Kinoshita M, Takahata R, Matsumoto Y, et al. CD 47 is an adverse prognostic factor and a therapeutic target in gastric cancer. Cancer Med. 2015;4(9):1322\u201333. https:\/\/doi.org\/10.1002\/cam4.478.","journal-title":"Cancer Med"},{"issue":"12","key":"1584_CR39","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1158\/1538-7445.AM2022-4260","volume":"4260","author":"J Li","year":"2022","unstructured":"Li J, Jia H, Ramsey E, Wu H, Long Y, Chen K, Abstract. PT886, an anti-claudin18.2\/anti-CD47 bispecific antibody constructed with the PACbody\u00ae and SPECpair\u00aetechnology platforms, exhibits robust anti-tumor activity in a pancreatic cancer xenograft model. Cancer Res. 2022;4260(12):4260. https:\/\/doi.org\/10.1158\/1538-7445.AM2022-4260.","journal-title":"Cancer Res"},{"issue":"1","key":"1584_CR40","first-page":"100070","volume":"10","author":"B Clark","year":"2024","unstructured":"Clark B, Moon J, Jackson D. Monoclonal Anti-CD47 Therapy and its Haematological Effects, including Anaemia and Thrombocytopenia. J Emerg Med Trauma Surg Care. 2024;10(1):100070. http:\/\/doi.org\/10779\/rmit.27583353","journal-title":"J Emerg Med Trauma Surg Care"},{"key":"1584_CR41","doi-asserted-by":"publisher","unstructured":"Xie Y, Guan P, Liu D, Peng Z, Zhang X, Shen L, et al. Claudin18. 2 positive gastric cancer: biology, tumor microenvironment, and therapeutic strategies. J Hematol Oncol. 2026;1937. https:\/\/doi.org\/10.1186\/s13045-026-01803-9.","DOI":"10.1186\/s13045-026-01803-9"},{"issue":"11","key":"1584_CR42","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.3390\/jpm11111095","volume":"11","author":"A Pellino","year":"2021","unstructured":"Pellino A, Brignola S, Riello E, Niero M, Murgioni S, Guido M, et al. Association of CLDN18 protein expression with clinicopathological features and prognosis in advanced gastric and gastroesophageal junction adenocarcinomas. J Pers Med. 2021;11(11):1095. https:\/\/doi.org\/10.3390\/jpm11111095.","journal-title":"J Pers Med"},{"issue":"1","key":"1584_CR43","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12916-022-02421-1","volume":"20","author":"K Jia","year":"2022","unstructured":"Jia K, Chen Y, Sun Y, Hu Y, Jiao L, Ma J, et al. Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18. 2-positive gastric cancer. BMC Med. 2022;20(1):223. https:\/\/doi.org\/10.1186\/s12916-022-02421-1.","journal-title":"BMC Med"},{"issue":"8","key":"1584_CR44","doi-asserted-by":"publisher","first-page":"viii32","DOI":"10.1093\/annonc\/mdy269.101","volume":"29","author":"D Moran","year":"2018","unstructured":"Moran D, Maurus D, Rohde C, Arozullah A. Prevalence of CLDN18. 2, HER2 and PD-L1 in gastric cancer samples. Ann Oncol. 2018;29(8):viii32. https:\/\/doi.org\/10.1093\/annonc\/mdy269.101","journal-title":"Ann Oncol"},{"issue":"4","key":"1584_CR45","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1007\/s10120-024-01505-6","volume":"27","author":"H Ogawa","year":"2024","unstructured":"Ogawa H, Abe H, Yagi K, Seto Y, Ushiku T. Claudin-18 status and its correlation with HER2 and PD-L1 expression in gastric cancer with peritoneal dissemination. Gastric Cancer. 2024;27(4):802\u201310. https:\/\/doi.org\/10.1007\/s10120-024-01505-6.","journal-title":"Gastric Cancer"},{"issue":"1","key":"1584_CR46","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s10637-024-01417-3","volume":"42","author":"J Yue","year":"2024","unstructured":"Yue J, Shao S, Zhou J, Luo W, Xu Y, Zhang Q, et al. A bispecific antibody targeting HER2 and CLDN18.2 eliminates gastric cancer cells expressing dual antigens by enhancing the immune effector function. Invest New Drugs. 2024;42(1):106\u201315. https:\/\/doi.org\/10.1007\/s10637-024-01417-3.","journal-title":"Invest New Drugs"},{"issue":"5","key":"1584_CR47","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00432-024-05740-3","volume":"150","author":"X Zhang","year":"2024","unstructured":"Zhang X, Wang H, Sun C. BiSpec Pairwise AI: guiding the selection of bispecific antibody target combinations with pairwise learning and GPT augmentation. J Cancer Res Clin Oncol. 2024;150(5):237. https:\/\/doi.org\/10.1007\/s00432-024-05740-3.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"23","key":"1584_CR48","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.3390\/cancers17233764","volume":"17","author":"A Dominguez Wiscovitch","year":"2025","unstructured":"Dominguez Wiscovitch A, Sanchez Mendez RJ, Chuy J. CLDN18. 2-Targeted Therapy in Gastrointestinal Cancers. Cancers (Basel). 2025;17(23):3764. https:\/\/doi.org\/10.3390\/cancers17233764.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"1584_CR49","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s00262-024-03673-x","volume":"73","author":"Z Ma","year":"2024","unstructured":"Ma Z, Zhou Z, Duan W, Yao G, Sheng S, Zong S, et al. DR30318, a novel tri-specific T cell engager for Claudin 18.2 positive cancers immunotherapy. Cancer Immunol Immunother. 2024;73(5):82. https:\/\/doi.org\/10.1007\/s00262-024-03673-x.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"1584_CR50","doi-asserted-by":"publisher","first-page":"17648","DOI":"10.1038\/s41598-024-68411-w","volume":"14","author":"E Choi","year":"2024","unstructured":"Choi E, Shin J, Ryu MH, Kim HD, Park YS. Heterogeneity of claudin 18.2 expression in metastatic gastric cancer. Sci Rep. 2024;14(1):17648. https:\/\/doi.org\/10.1038\/s41598-024-68411-w.","journal-title":"Sci Rep"},{"issue":"2","key":"1584_CR51","doi-asserted-by":"publisher","first-page":"303","DOI":"10.5230\/jgc.2025.25.e2","volume":"25","author":"SM Son","year":"2025","unstructured":"Son SM, Woo CG, Lee OJ, Lee SK, Cho M, Lee YP, et al. Discordance in Claudin 18.2 Expression Between Primary and Metastatic Lesions in Patients With Gastric Cancer. J Gastric Cancer. 2025;25(2):303\u201317. https:\/\/doi.org\/10.5230\/jgc.2025.25.e2.","journal-title":"J Gastric Cancer"},{"issue":"4","key":"1584_CR52","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s10147-026-02972-w","volume":"31","author":"S Nagano","year":"2026","unstructured":"Nagano S, Kurokawa Y, Hagi T, Motoyama Y, Saito T, Takahashi T, et al. Intratumoral heterogeneity and chemotherapy-induced alteration of CLDN18.2 expression in resectable gastric cancer. Int J Clin Oncol. 2026;31(4):621\u201329. https:\/\/doi.org\/10.1007\/s10147-026-02972-w.","journal-title":"Int J Clin Oncol"},{"key":"1584_CR53","doi-asserted-by":"publisher","unstructured":"Yamamoto K, Nakayama I, Sakamoto N, Matsubara Y, Miyashita Y, Kobayashi A, et al. Temporal dynamics of CLDN18. 2 expression following zolbetuximab treatment in advanced gastric cancer. ESMO Gastrointest Oncol. 2025;9100206. https:\/\/doi.org\/10.1016\/j.esmogo.2025.100206.","DOI":"10.1016\/j.esmogo.2025.100206"},{"issue":"9","key":"1584_CR54","doi-asserted-by":"publisher","first-page":"e012683","DOI":"10.1136\/jitc-2025-012683","volume":"13","author":"SH Lim","year":"2025","unstructured":"Lim SH, Kuwata T, An M, Hong JY, Kim ST, Matsubara Y, et al. Dynamic modulation of claudin18. 2 expression and remodeling of the tumor microenvironment in gastric cancer during chemo-immunotherapy. J Immunother Cancer. 2025;13(9):e012683. https:\/\/doi.org\/10.1136\/jitc-2025-012683.","journal-title":"J Immunother Cancer"},{"key":"1584_CR55","doi-asserted-by":"publisher","unstructured":"Kwak Y, Kim TY, Nam SK, Hwang HJ, Han D, Oh HJ, et al. Clinicopathologic and molecular characterization of stages II-IV gastric cancer with Claudin 18.2 expression. Oncologist. 2025;30(2). https:\/\/doi.org\/10.1093\/oncolo\/oyae238.","DOI":"10.1093\/oncolo\/oyae238"},{"key":"1584_CR56","doi-asserted-by":"publisher","unstructured":"Castillo D, Guo M, Shah P, Hazeltin M, Tai D, Al-Manaseer F, et al. Distinct clinicopathological and survival profiles of CLDN18. 2 and PD-L1 expression in advanced gastric cancer and gastroesophageal junction adenocarcinoma. ESMO Gastrointest Oncol. 2025;10100261. https:\/\/doi.org\/10.1016\/j.esmogo.2025.100261.","DOI":"10.1016\/j.esmogo.2025.100261"},{"issue":"1","key":"1584_CR57","doi-asserted-by":"publisher","first-page":"78","DOI":"10.21147\/j.issn.1000-9604.2024.01.08","volume":"36","author":"C Qi","year":"2024","unstructured":"Qi C, Chong X, Zhou T, Ma M, Gong J, Zhang M, et al. Clinicopathological significance and immunotherapeutic outcome of claudin 18.2 expression in advanced gastric cancer: A retrospective study. Chin J Cancer Res. 2024;36(1):78\u201389. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2024.01.08.","journal-title":"Chin J Cancer Res"},{"issue":"2","key":"1584_CR58","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/leu.2015.214","volume":"30","author":"C Krupka","year":"2016","unstructured":"Krupka C, Kufer P, Kischel R, Zugmaier G, Lichtenegger FS, K\u00f6hnke T, et al. Blockade of the PD-1\/PD-L1 axis augments lysis of AML cells by the CD33\/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism. Leukemia. 2016;30(2):484\u201391. https:\/\/doi.org\/10.1038\/leu.2015.214.","journal-title":"Leukemia"},{"key":"1584_CR59","doi-asserted-by":"publisher","unstructured":"Wang X, He J, Ding G, Tang Y, Wang Q. Overcoming resistance to PD-1 and CTLA-4 blockade mechanisms and therapeutic strategies. Front Immunol. 2025;161688699. https:\/\/doi.org\/10.3389\/fimmu.2025.1688699.","DOI":"10.3389\/fimmu.2025.1688699"},{"issue":"9","key":"1584_CR60","doi-asserted-by":"publisher","first-page":"e693","DOI":"10.1016\/S2352-3026(24)00186-8","volume":"11","author":"NW Van De Donk","year":"2024","unstructured":"Van De Donk NW, Chari A, Mateos MV. Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies. Lancet Haematol. 2024;11(9):e693\u2013707. https:\/\/doi.org\/10.1016\/S2352-3026(24)00186-8.","journal-title":"Lancet Haematol"},{"issue":"10","key":"1584_CR61","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1182\/blood.2022015956","volume":"140","author":"N Philipp","year":"2022","unstructured":"Philipp N, Kazerani M, Nicholls A, Vick B, Wulf J, Straub T, et al. T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals. Blood. 2022;140(10):1104\u201318. https:\/\/doi.org\/10.1182\/blood.2022015956.","journal-title":"Blood"},{"issue":"6","key":"1584_CR62","doi-asserted-by":"publisher","first-page":"6719","DOI":"10.1158\/1538-7445.AM2024-6719","volume":"84","author":"L Newhook","year":"2024","unstructured":"Newhook L, Bhojane P, Stahl K, Escalante NE, Repenning P. Abstract 6719: TriTCE Co Stim: A next generation trispecific T cell engager platform with integrated CD28 costimulation, engineered to improve responses in the treatment of solid tumors. Cancer Res. 2024;84(6):6719. https:\/\/doi.org\/10.1158\/1538-7445.AM2024-6719.","journal-title":"Cancer Res"},{"issue":"1","key":"1584_CR63","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12964-023-01406-8","volume":"22","author":"S Liu","year":"2024","unstructured":"Liu S, Zhang Z, Jiang L, Zhang M, Zhang C, Shen L. Claudin-18.2 mediated interaction of gastric Cancer cells and Cancer-associated fibroblasts drives tumor progression. Cell Commun Signal. 2024;22(1):27. https:\/\/doi.org\/10.1186\/s12964-023-01406-8.","journal-title":"Cell Commun Signal"},{"issue":"12","key":"1584_CR64","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1136\/gutjnl-2024-332371","volume":"73","author":"T Zhou","year":"2024","unstructured":"Zhou T, Hou X, Yan J, Li L, Xie Y, Bai W, et al. CD64(+) fibroblast-targeted vilanterol and a STING agonist augment CLDN18.2 BiTEs efficacy against pancreatic cancer by reducing desmoplasia and enriching stem-like CD8(+) T cells. Gut. 2024;73(12):1984\u201398. https:\/\/doi.org\/10.1136\/gutjnl-2024-332371.","journal-title":"Gut"},{"key":"1584_CR65","doi-asserted-by":"publisher","unstructured":"Wang Y, Ding N, Qi L, Chen W, Wu P. Immunopharmacology of gastric cancer\u2013deciphering immune cell subset responses and nanoparticle-mediated targeting. Front Pharmacol. 2025;161611234. https:\/\/doi.org\/10.3389\/fphar.2025.1611234.","DOI":"10.3389\/fphar.2025.1611234"},{"issue":"21","key":"1584_CR66","doi-asserted-by":"publisher","first-page":"4449","DOI":"10.1158\/1078-0432.Ccr-22-3667","volume":"29","author":"G Leclercq-Cohen","year":"2023","unstructured":"Leclercq-Cohen G, Steinhoff N, Albert\u00ed Servera L, Nassiri S, Danilin S, Piccione E, et al. Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies. Clin Cancer Res. 2023;29(21):4449\u201363. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-22-3667.","journal-title":"Clin Cancer Res"},{"key":"1584_CR67","doi-asserted-by":"publisher","unstructured":"Ferreros P, Trapero I. Interleukin Inhibitors in Cytokine Release Syndrome and Neurotoxicity Secondary to CAR-T Therapy. Diseases. 2022;10(3). https:\/\/doi.org\/10.3390\/diseases10030041.","DOI":"10.3390\/diseases10030041"},{"key":"1584_CR68","doi-asserted-by":"publisher","unstructured":"Inamoto R, Takahashi N, Yamada Y. Claudin18.2 in Advanced Gastric Cancer. Cancers (Basel). 2023;15(24). https:\/\/doi.org\/10.3390\/cancers15245742.","DOI":"10.3390\/cancers15245742"},{"key":"1584_CR69","doi-asserted-by":"publisher","unstructured":"Liu Y, Nguyen AW, Maynard JA. Engineering antibodies for conditional activity in the solid tumor microenvironment. Curr Opin Biotechnol. 2022;78102809. https:\/\/doi.org\/10.1016\/j.copbio.2022.102809.","DOI":"10.1016\/j.copbio.2022.102809"},{"issue":"6","key":"1584_CR70","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1016\/s1470-2045(23)00159-6","volume":"24","author":"H Ludwig","year":"2023","unstructured":"Ludwig H, Terpos E, Van De Donk N, Mateos MV, Moreau P, Dimopoulos MA, et al. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. Lancet Oncol. 2023;24(6):e255\u201369. https:\/\/doi.org\/10.1016\/s1470-2045(23)00159-6.","journal-title":"Lancet Oncol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01584-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01584-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01584-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:16:28Z","timestamp":1788351388000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01584-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1584"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01584-x","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"assertion":[{"value":"10 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"207"}}